152 related articles for article (PubMed ID: 21448930)
1. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
3. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
4. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
5. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
6. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
7. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
8. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.
Kittaka M; Yoshimoto T; Schlosser C; Rottapel R; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2020 Feb; 35(2):382-395. PubMed ID: 31613396
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
[TBL] [Abstract][Full Text] [Related]
10. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
[TBL] [Abstract][Full Text] [Related]
11. TRAF family member-associated NF-κB activator (TANK) induced by RANKL negatively regulates osteoclasts survival and function.
Wu M; Wang Y; Deng L; Chen W; Li YP
Int J Biol Sci; 2012; 8(10):1398-407. PubMed ID: 23139637
[TBL] [Abstract][Full Text] [Related]
12. SLAT negatively regulates RANKL-induced osteoclast differentiation.
Youn BU; Kim K; Kim JH; Lee J; Moon JB; Kim I; Park YW; Kim N
Mol Cells; 2013 Sep; 36(3):252-7. PubMed ID: 23996528
[TBL] [Abstract][Full Text] [Related]
13. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
14. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
15. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.
Miyauchi Y; Ninomiya K; Miyamoto H; Sakamoto A; Iwasaki R; Hoshi H; Miyamoto K; Hao W; Yoshida S; Morioka H; Chiba K; Kato S; Tokuhisa T; Saitou M; Toyama Y; Suda T; Miyamoto T
J Exp Med; 2010 Apr; 207(4):751-62. PubMed ID: 20368579
[TBL] [Abstract][Full Text] [Related]
16. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.
GuezGuez A; Prod'homme V; Mouska X; Baudot A; Blin-Wakkach C; Rottapel R; Deckert M
J Biol Chem; 2010 Jul; 285(27):20952-63. PubMed ID: 20439986
[TBL] [Abstract][Full Text] [Related]
17. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
18. Honokiol inhibits osteoclast differentiation and function in vitro.
Hasegawa S; Yonezawa T; Ahn JY; Cha BY; Teruya T; Takami M; Yagasaki K; Nagai K; Woo JT
Biol Pharm Bull; 2010; 33(3):487-92. PubMed ID: 20190414
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.
Ghayor C; Correro RM; Lange K; Karfeld-Sulzer LS; Grätz KW; Weber FE
J Biol Chem; 2011 Jul; 286(27):24458-66. PubMed ID: 21613210
[TBL] [Abstract][Full Text] [Related]
20. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]